文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评价含贝达喹啉口服短程方案治疗中国耐多药结核病患者有效性与安全性的实用性随机对照试验:PROSPECT 研究方案

A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
PubMed 文献 · Trials · 2024-04-01

PROSPECT 是一项 4 期、随机、开放标签、对照、非劣效性试验,在中国 17 家中心比较含贝达喹啉的 9 个月全口服短程方案与不含贝达喹啉的全口服短程方案治疗成人耐多药结核病。主要结局为治疗完成(第 40 周)时有利治疗结局的比例,假设 α=0.025(单侧检验)、80% 把握度、15% 非劣效界值、10% 失访率,每组需 106 例(共 212 例)。

要点

  • 含贝达喹啉组采用改良 STREAM C 方案,用利奈唑胺和环丝氨酸替代乙胺丁醇、吡嗪酰胺和丙硫异烟胺。
  • 对第 16 周痰培养仍阳性的参与者,贝达喹啉疗程从 6 个月延长至 9 个月。
  • 利奈唑胺(600 mg)每日给药,依据观察到的获益与危害至少持续 24 周。

核心结论

  • PROSPECT 旨在评估含贝达喹啉短程方案在中国 17 家中心治疗耐多药结核病的安全性与有效性,并为中国国家结核病规划指导下短程方案的实施提供高质量数据。
  • PROSPECT 还将探索对第 16 周痰未转阴的参与者延长含贝达喹啉 9 个月短程方案给药的潜在获益。

研究设计与样本

  • 4 期、随机、开放标签、对照、非劣效性试验,纳入中国 18-65 岁成人耐多药结核病患者,每组需 106 例(共 212 例)。
  • 试验设计主要参照 STREAM 第 2 期研究,并纳入南非规划性数据及 2019 年中国耐多药/利福平耐药结核病治疗专家共识建议。
  • 主要结局为治疗完成(第 40 周)时有利治疗结局的参与者比例,治疗完成后 48 周时同一测量为次要结局。
  • 假设 α=0.025(单侧检验)、80% 把握度、15% 非劣效界值、10% 失访率。

关键数值与推荐

  • 试验组接受改良 STREAM C 方案,用两种 B 组药物利奈唑胺和环丝氨酸替代三种 C 组药物乙胺丁醇、吡嗪酰胺和丙硫异烟胺,对确认异烟肼耐药病例省略高剂量异烟肼。
  • 对第 16 周痰培养阳性的参与者,贝达喹啉疗程从 6 个月延长至 9 个月。
  • 对照组接受改良 STREAM B 方案,不含高剂量异烟肼和注射用卡那霉素,并采用试验组的利奈唑胺和环丝氨酸剂量、疗程及给药方式。
  • 利奈唑胺(600 mg)每日给药,依据观察到的获益与危害至少持续 24 周。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has significantly impeded TB control efforts in China. METHODS: This phase 4, randomized, open-label, controlled, non-inferiority trial aims to assess the efficacy and safety of a 9-month all-oral SCR containing bedaquiline (BDQ) versus an all-oral SCR without BDQ for adult MDR-TB patients (18-65 years) in China. The trial design mainly mirrors that of the "Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB" (STREAM) stage 2 study, while also incorporating programmatic data from South Africa and the 2019 consensus recommendations of Chinese MDR/RR-TB treatment experts. Experimental arm participants will receive a modified STREAM regimen C that replaces three group C drugs, ethambutol (EMB), pyrazinamide (PZA), and prothionamide (PTO), with two group B drugs, linezolid (LZD) and cycloserine (CS), while omitting high-dose isoniazid (INH) for confirmed INH-resistant cases. BDQ duration will be extended from 6 to 9 months for participants with Mycobacterium tuberculosis-positive sputum cultures at week 16. The control arm will receive a modified STREAM regimen B without high-dose INH and injectable kanamycin (KM) that incorporates experimental arm LZD and CS dosages, treatment durations, and administration methods. LZD (600 mg) will be given daily for ≥ 24 weeks as guided by observed benefits and harm. The primary outcome measures the proportion of participants with favorable treatment outcomes at treatment completion (week 40), while the same measurement taken at 48 weeks post-treatment completion is the secondary outcome. Assuming an α = 0.025 significance level (one-sided test), 80% power, 15% non-inferiority margin, and 10% lost to follow-up rate, each arm requires 106 participants (212 total) to demonstrate non-inferiority. DISCUSSION: PROSPECT aims to assess the safety and efficacy of a BDQ-containing SCR MDR-TB treatment at seventeen sites across China, while also providing high-quality data to guide SCRs administration under the direction of the China National Tuberculosis Program for MDR-TB. Additionally, PROSPECT will explore the potential benefits of extending the administration of the 9-month BDQ-containing SCR for participants without sputum conversion by week 16. TRIAL REGISTRATION: ClinicalTrials.gov NCT05306223. Prospectively registered on 16 March 2022 at https://clinicaltrials.gov/ct2/show/NCT05306223?term=NCT05306223&draw=1&rank=1 {2}.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao J, Gao M, Du J, et al. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. Trials. 2024. PMID: 38561815. doi:10.1186/s13063-024-07946-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。